Image

LucenceINSIGHT
For Healthcare Providers


LucenceINSIGHT™ is a multi-cancer early detection (MCED) tool that screens for the signal of multiple cancers in a simple blood draw.

Leveraging proprietary amplicon-based technology to screen for the signal of cancer with a sensitivity of 80.9% and a specificity of 99%1, the test identifies single nucleotide variations (SNVs), indels and cancer associated viruses such as Epstein-Barr virus (EBV) and Human Papillomavirus (HPV) in circulating tumor DNA (ctDNA).

Utilizing data from the analysis, a localization signal is derived and used to predict up to 2 sites where the cancer signal might have originated from. LucenceINSIGHT™ lists these findings as Predicted Signal Localization. 

With a prediction accuracy of 88%1, the Predicted Signal Localization helps guide further confirmatory diagnostic testing. 

ImageImage
Image

Cancers covered by LucenceINSIGHT


There are 50 cancer types covered by LucenceINSIGHT™ PLUS. LucenceINSIGHT covers the 12 cancers highlighted in orange.

Image
Image

Providing INSIGHT to your patients


Offering LucenceINSIGHT™ at your healthcare facility begins simply with a quick introduction from our patient excellence team.

If you would like to find out more about LucenceINSIGHT™, fill up this form here and we will get in touch with you shortly.


Email Us
Image

Frequently Asked Questions For Physicians


Image

References

  1. Data on file.
Image
SINGAPORE OFFICE

211 Henderson Rd #04-02
Henderson Industrial Park
Singapore 159552

sales.asean@lucence.com
+65 6592 5102

HONG KONG OFFICE

Rooms 05-15, 13A/F, South Tower World Finance Centre Harbour City,
17 Canton Road, Tsim Sha Tsui, Kowloon Hong Kong

sales.hk@lucence.com
+852 5182 7199

FOLLOW US


©2023 Lucence Diagnostics Pte Ltd. All rights reserved. All logos and trademarks are the property of Lucence or their respective owners. The information on this site is intended for audiences in Singapore and Hong Kong only.